Zimbabwe has turned down a major American healthcare agreement valued at $367m (£272m) over five years over the United States' insistence on confidential information.
The decision became public following a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "skewed".
An official spokesperson has since clarified that the United States was seeking genetic material for scientific study and commercial gain while refused to share the benefits from any future medical innovations.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued dialogue to secure a deal suitable to both sides so the country's critical HIV treatment initiative can continue.
Broader Context
This development comes after a similar case in neighbouring Kenya, where a court blocked a related health funding agreement after concerns were raised about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and accountability.
According to reports, 16 African countries have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Effectively, our nation would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our citizens should a future pandemic arise."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its push of one-on-one health agreements were undermining structures already set up through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome continued discussions with our US partners on how future co-operation might be arranged in a way that honours the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but urged that negotiations need to persist given that much of the country's Aids initiatives relied on external financing.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the ongoing tensions between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.